secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0000950170-25-040294
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gemini priming attenuates inflammation in human PBMCs; Phase 1b data expected mid-2025
--------------------------------------------------------------------------------

- Gemini significantly decreased proinflammatory cytokines and increased anti-inflammatory cytokines vs. placebo in PBMCs challenged with HMGB-1 and LPS.
- Revelation anticipates demonstrating same protective effect in cells from CKD patients in ongoing Phase 1b PRIME study.
- Top-line safety, tolerability, and cellular protection data from Phase 1b expected by mid-2025.
- Results support future development of GEM-CKD, GEM-AKI, and GEM-PSI programs.
- CEO James Rolke called results 'game-changing' for Gemini's potential in target indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025040294/0000950170-25-040294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025040294/revb-20250317.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer